AACR: Novartis hops on KRAS craze with early data, seeking to improve on undruggable target
AACR: Novartis hops on KRAS craze with early data, seeking [...]
AACR: Novartis hops on KRAS craze with early data, seeking [...]
AACR: C4’s multiple myeloma data prompts dosing switch, giving patients [...]
Cut the music: Kaleido calls it quits after FDA crackdown [...]
In just 72 words, BioCryst pauses enrollment for 3 mid-stage [...]
AACR: Blueprint wants to make resistance to AstraZeneca’s Tagrisso futile [...]
Genfit bounces back from omicron to keep phase 3 trial [...]
Final Aduhelm coverage decision keeps the door cracked open for [...]
GenSight seeks cash as runway enters final year with gene [...]
Chutes & Ladders—Fierce Biotech launches Layoff Tracker amid dizzying number [...]
Pandemic tears up Biophytis’ plans, limiting data and blowing up [...]